MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease

Dragana Mijac¹*, Irena Vukovic-Petrovic², Vera Mijac², Vladimir Perovic², Natasa Milic³, Srdjan Djuranovic¹, Daniela Bojic⁵, Dragan Popovic¹, Djordje Culafic¹, Miodrag Krstic¹, Goran Jankovic¹, Vera Pravica², Milos Markovic²

¹ Clinic for Gastroenterology and Hepatology, Faculty of Medicine, University of Belgrade, Clinical Center of Serbia, Belgrade, Serbia, ² Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, ³ Department for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, ⁴ Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States of America, ⁵ Department of Gastroenterology, University Hospital Zvezdara, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

* draganamijac@gmail.com

Abstract

Background
Inflammatory bowel disease (IBD) is a chronic disease of unknown etiology in which genetic factors contribute to development of disease. Single nucleotide polymorphisms (SNPs) in multidrug resistance 1 (MDR1) gene encoding transporter P-glycoprotein have been associated with IBD, but their role in disease susceptibility remains unclear. Therefore, the aim of this study was to investigate the association of three MDR1 polymorphisms, C1236T (rs1128503), G2677T/A (rs2032582) and C3435T (rs1045642), with Serbian IBD patients.

Methods
A total of 206 IBD patients, 107 Crohn’s disease (CD) and 99 ulcerative colitis (UC), and 255 healthy controls were included in the study. All subjects were genotyped using TaqMan SNP genotyping assays. Comparisons between the groups were performed using the Pearson Chi-square test. False discovery rate according to Benjamini-Hochberg procedure was applied to adjust for multiple comparisons.

Results
Carriers of T allele of all three MDR1 SNPs were more common in UC patients compared to healthy controls, suggesting predisposing role of T allele of these SNPs in UC pathogenesis. Consistently, TT genotype of C1236T and TTT haplotype were also found more frequently in UC patients. On the other hand, C allele and CC genotype of C1236T and C3435T, as well as G allele and GG genotype of G2677T/A were more frequent in healthy subjects, implying protective role of these variants in UC. Likewise, CGC haplotype and CGC/CGC diplotype were more frequent in controls. Contrary to UC, no statistical difference was observed between CD patients and controls in any of the SNPs analyzed.
Conclusion

MDR1 gene variants and haplotypes were associated with UC in Serbian IBD patients, further supporting their potential role in susceptibility to UC.

Introduction

Inflammatory bowel disease (IBD) with its major forms, ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, relapsing, lifelong disorder of the gastrointestinal (GI) tract. IBD occurs worldwide and due to the increase in its incidence noted in the last 50 years it is becoming an important global health problem [1]. Despite extensive studies, the etiopathogenesis of IBD is still not fully understood. However, evidence suggests that it is multifactorial and comprises aberrant immune response to microbiota on mucosal barrier of GI in genetically susceptible individuals [2]. Linkage studies in families clearly emphasize the importance of genetic factors to disease development. Between 5 and 23% of patients with IBD have an affected first-degree relative, with up to 25% chance that families with CD have members with UC and vice versa, which is consistent with the hypothesis that some risk gene alleles are common to both disorders, while other susceptibility genes may be unique specifically either to UC or CD [3, 4].

Advances in genetic methodology in the last decades, from candidate gene approach to genome-wide association studies (GWAS), have led to identification of many genes that could be related to IBD [4]. One of the candidate genes that got a lot of attention is ABCB1 (ATP-binding cassette, subfamily B 1 gene), also called multidrug resistance 1 (MDR1) gene. MDR1 encodes P-glycoprotein 170 (P-gp), an ATP-dependent drug transport efflux pump, highly expressed in many cells and epithelial surfaces, including the epithelium of GI tract [5]. In the gut, P-gp is expressed constitutively on the apical surfaces of the superficial epithelial cell layer, with the lower levels of expression in stomach, and gradual increase from duodenum towards ileum and distal parts of intestine [6]. The physiological function of P-gp has not been elucidated thus far. However, it is known that substrates for the P-gp pump include a variety of structurally and pharmacologically distinct hydrophobic compounds, such as toxins and drugs. Pgp could act as a protective barrier to keep toxins out of the body by secreting them into bile, urine, and intestinal lumen, and thereby preventing their accumulation in critical organs [7, 8]. It might also play a critical role in host-bacterial interactions in the gastrointestinal tract and maintenance of intestinal homeostasis. Therefore, it is possible that mutations of the MDR1 gene could affect the uptake of bacterial toxins and xenobiotics and thus have a role in the development of IBD. In line with this notion are the results from the study with mdr1a knockout mice [9]. When kept in specific pathogen-free environment, those mice develop spontaneous colitis which resembles UC in humans, but shares some features of CD, as well. In humans, MDR1 gene is contained within the region on chromosome 7q that has been linked with IBD [10]. Moreover, it was shown that MDR1 expression is significantly reduced in colonic tissue of patients with UC [11].

More than 50 single-nucleotide polymorphisms (SNPs) of MDR1 that occur naturally in humans have been identified thus far and some of them were related to altered P-gp expression and function [12, 13]. Three most common SNPs that have been repeatedly shown to predict changes in the function of P-gp are synonymous SNPs C1236T (rs1128503) in exon 12 and C3435T (rs1045642) in exon 26 and non-synonymous, triallelic SNP G2677T/A (Ala893Ser/Thr or rs2032582) located in exon 21 [14]. The association of C3435T and G2677T/A with
IBD has been extensively studied in the past years. One of the first observations that both T allele and TT genotype of C3435T polymorphism were more frequently present among UC subjects came from a German study [15]. The positive association of G allele of 2677 and IBD was also shown in a large multicenter North American study [16]. However, a large number of later reports that analyzed different allele combinations of those SNPs in IBD patients gave conflicting results [7, 17–20]. Similarly to C3435T and G2677T/A, several studies has recently addressed the role of C1236T in IBD yielding also inconclusive results [20–25].

Considerable geographical and ethnical variations in IBD incidence have been demonstrated worldwide [26]. Likewise, MDR1 expression and P-gp function also show wide individual and interethnic differences, probably influenced by both environmental and genetic factors [27]. So far, significant interethnic differences in allele and genotype frequencies of MDR1 SNPs have been reported, but most studies were done on populations from Western Europe, while data from Eastern European countries and Serbia in particular, are limited. Therefore, the aim of this study was to assess the three-locus genotype pattern for C1236T, G2677T/A and C3435T variants in Serbian patients with IBD.

**Material and methods**

**Subjects**

The study involved a total of 206 IBD patients and 255 unrelated healthy controls. IBD group comprised 107 CD patients and 99 UC patients followed up for IBD at Clinic for Gastroenterology and Hepatology, Faculty of Medicine, University Belgrade, Clinical Center of Serbia in the period from June 2012 to June 2014. Diagnosis of CD and UC was determined according to established guidelines based on standard clinical, radiological, endoscopic and histological criteria [28, 29]. Phenotype characteristics of UC and CD were defined according to the Montreal classification [30]. The clinical disease activity was calculated using the Mayo score and Crohn’s Disease Activity Index (CDAI) for UC and CD patients, respectively [31, 32]. Clinical characteristics of the patients included in the study are summarized in Table 1. Matching blood samples were obtained from 255 healthy blood donors using centralized procurement through the National Blood Transfusion Institute. Informed written consent was obtained from all individuals before blood sampling and the study was approved by the Ethic Committees of the Faculty of Medicine–University of Belgrade and Clinical Center of Serbia.

**Genotyping**

Genomic DNA was extracted from peripheral blood using the GeneJET whole blood genomic DNA purification mini kit (Fermentas Thermo Fisher Scientific Inc, Germany). The concentration and purity of DNA were determined by measuring absorbance at 260 nm and 280 nm. Detection of MDR1 SNPs were done by real-time PCR using commercial primers and TaqMan probes (C_7586662_10 for C1236T, C_11711720C_30 and C_11711720D_40 for G2677T/A and C_7586657_20 for C3435T, all from Applied Biosystems Inc, USA) with Maxima Probe qPCR Master Mix (Fermentas Thermo Fisher Scientific Inc) following procedure recommended by the manufacturer of oligonucleotide mixes.

**Statistical analysis**

Statistical analyses were performed using the statistical package for social sciences, version 20 (SPSS, Chicago, USA). The estimation of haplotypes and diplotype frequencies was done by the Expectation-Maximization algorithm using Arlequin 3.5.1.3 [33]. Comparisons between allele, genotype, haplotype and diplotype frequencies in different populations were performed
using the Pearson Chi-square test. Two-sided p values, odds ratios (OR) and 95% confidence intervals (CI) were calculated. False discovery rate according to Benjamini-Hochberg procedure was applied to adjust for multiple comparisons. Calculations for the critical value were done with a false discovery rate of 5%.

### Table 1. Main clinical characteristics of CD and UC patients.

| Characteristic                              | CD          | UC          |
|---------------------------------------------|-------------|-------------|
| Number                                      | 107         | 99          |
| Sex–n (%)                                   |             |             |
| Male                                        | 62 (57.9)   | 54 (54.5)   |
| Female                                      | 45 (42.1)   | 45 (45.5)   |
| Age (years, median, min–max)                | 40 (18–68)  | 42 (19–70)  |
| Age at diagnosis (years, median, min–max)   | 32.5 (14–67)| 36.6 (2–67) |
| Disease duration (years, median, min–max)   | 6.6 (0–31)  | 5.5 (0–26)  |
| Localisation–n (%)                          |             |             |
| CD Ileal ± UGI                              | 27 + 1 = 28 (26.2) |
| Ileocolonic ± UGI                           | 45 + 7 = 52 (48.6) |
| Colonic ± UGI                               | 27 + 0 = 27 (25.2) |
| UGI (only)                                  | 0           |             |
| UC Proctitis                                | 2 (2.0)     |             |
| Left side colitis                           | 35 (35.4)   |             |
| Extensive colitis                           | 59 (59.6)   |             |
| IPAA-pouchitis                              | 3 (3.0)     |             |
| Behaviour–n (%)                             |             |             |
| Inflammatory ± perianal                     | 22 + 12 = 34 (31.7) |
| Structuring ± perianal                      | 42 + 15 = 57 (53.3) |
| Penetrating ± perianal                      | 11 + 5 = 16 (15.0) |
| Perianal (only)                             | 0           |             |
| Perianal (any)                              | 32 (29.9)   |             |
| Extra-intestinal manifestations–n (%)       |             |             |
| Current                                     | 18 (16.8)   | 27 (27.3)   |
| Previous                                    | 16 (15.0)   | 12 (12.1)   |
| Never                                       | 73 (68.2)   | 60 (60.6)   |
| Activity index (median, min–max)            | CDAI 151 (44–400) | Mayo 6 (0–12) |
| Early disease (up to 18 months)–n (%)       | 40 (37.4)   | 45 (45.5)   |
| Surgery–n (%)                               | 53 (49.5)   | 3 (3)       |
| Age at Surgery (years, median, min–max)     | 34.7 (19–66)| 48.7 (30–65)|
| Disease duration to surgery (years, median) | 2.9         | 2.3         |
| Corticosteroid-dependent–n (%)              | 54 (50.5)   | 32 (32.3)   |
| Corticosteroid-refractory–n (%)             | 14 (13.1)   | 4 (4.0)     |
| Anti-TNF therapy                            |             |             |
| Yes                                         | 42 (39.3)   | 7 (7.1)     |
| No                                          | 65 (60.7)   | 92 (92.9)   |
| Smoking–n (%)                               |             |             |
| At diagnosis                                | 25 (23.4)   | 10 (10.1)   |
| Ex smoker                                   | 11 (10.3)   | 19 (19.2)   |
| Never                                       | 71 (66.3)   | 70 (70.7)   |

UGI–upper gastrointestinal; IPAA–ileo-pouch anal anastomosis; CDAI–Crohn’s disease activity index; TNF–Tumor necrosis factor

[https://doi.org/10.1371/journal.pone.0194536.t001](https://doi.org/10.1371/journal.pone.0194536.t001)
Results
Genotypes of C1236T, G2677T/A and C3453T SNPs were in Hardy-Weinberg equilibrium in the control group, as well as in all cases (CD and UC groups). The distribution of alleles and genotypes for C3435T, G2677T/A and C1236T in our study population is presented in Table 2. Overall, the frequencies of both alleles and genotypes of all three investigated MDR1 SNPs were significantly different in UC patients compared to healthy subjects, whereas no statistical difference was observed between CD and controls in any of the SNPs analyzed (Table 2).

Regarding the C1236T SNP, minor T allele and TT genotype of C1236T were more frequent in UC patients compared to healthy controls (59.1% vs. 44.1%; \(p = 0.0003, \text{OR} = 1.830, 95\%CI [1.312–2.552]\) for T allele and 34.3% vs. 21.6%; \(p = 0.013, \text{OR} = 1.902 [1.141–3.171]\) for TT genotype, respectively), suggesting predisposing role of T allele in UC. Conversely, CC genotype of C1236T could be recognized as a possible protective factor since it was significantly more common among healthy subjects than in UC patients (33.3% vs. 16.2%; \(p = 0.001, \text{OR} = 0.386 [0.213–0.699]\)). Likewise, T allele of C3435T was more common in UC patients compared to controls (60.1% vs. 48.6%; \(p = 0.006, \text{OR} = 1.426 [1.022–1.990]\)), whereas the frequency of CC genotype was significantly lower in UC patients than in controls (13.1% vs. 27.5%; \(p = 0.004, \text{OR} = 0.4 [0.210–0.761]\)). The allele and genotype distributions of triallelic G2677T/A SNP also differed significantly between UC patients and healthy subjects implying

| MDR1 SNP          | Controls (n = 255) | CD (n = 107) | p value* | UC (n = 99) | p value* |
|-------------------|-------------------|-------------|----------|-------------|----------|
|                   | n (%)             | n (%)       |          | n (%)       |          |
| **C1236T (rs1128503)** |                   |             |          |             |          |
| Allele            |                   |             |          |             |          |
| C                 | 285 (55.9)        | 126 (58.9)  | 0.458    | 81 (40.9)   | 0.0003** |
| T                 | 225 (44.1)        | 88 (41.1)   |          | 117 (59.1)  |          |
| Genotype          |                   |             |          |             |          |
| CC                | 85 (33.3)         | 38 (35.5)   | 0.708    | 16 (16.2)   | 0.002**  |
| CT                | 115 (45.1)        | 50 (46.7)   |          | 49 (49.5)   |          |
| TT                | 55 (21.6)         | 19 (17.8)   |          | 34 (34.3)   |          |
| **G2677T/A (rs2032582)** |                  |             |          |             |          |
| Allele            |                   |             |          |             |          |
| G                 | 282 (55.3)        | 125 (58.4)  | 0.616    | 84 (42.4)   | 0.004**  |
| T                 | 221 (43.3)        | 85 (39.7)   |          | 113 (57.1)  |          |
| A                 | 7 (1.4)           | 4 (1.9)     |          | 1 (0.5)     |          |
| Genotype          |                   |             |          |             |          |
| GG                | 83 (32.5)         | 35 (32.7)   | 0.674    | 16 (16.2)   | 0.007**  |
| GT                | 112 (43.9)        | 52 (48.6)   |          | 51 (51.5)   |          |
| GA                | 4 (1.6)           | 3 (2.8)     |          | 1 (1.0)     |          |
| TT                | 53 (20.8)         | 16 (15.0)   |          | 31 (31.3)   |          |
| TA                | 3 (1.2)           | 1 (0.9)     |          | 0 (0)       |          |
| AA                | 0 (0)             | 0 (0)       |          | 0 (0)       |          |
| **C3435T (rs1045642)** |                |             |          |             |          |
| Allele            |                   |             |          |             |          |
| C                 | 262 (51.4)        | 94 (43.9)   | 0.067    | 79 (39.9)   | 0.006**  |
| T                 | 248 (48.6)        | 120 (56.1)  |          | 119 (60.1)  |          |
| Genotype          |                   |             |          |             |          |
| CC                | 70 (27.5)         | 33 (30.8)   | 0.449    | 13 (13.1)   | 0.013**  |
| CT                | 122 (47.8)        | 54 (50.5)   |          | 53 (53.5)   |          |
| TT                | 63 (24.7)         | 20 (18.7)   |          | 33 (33.3)   |          |

*p values were calculated using Chi-square test
**significant after adjustment for multiple test comparison

https://doi.org/10.1371/journal.pone.0194536.t002
that allele T could be considered as a risk factor and G allele as protective factor in UC. Namely, T allele and TT genotype were more frequent in UC patients (57.1% vs. 43.3%; p = 0.001, OR = 1.739 [1.248–2.422] for T allele and 31.3% vs. 20.8%; p = 0.037, OR 1.738 [1.032–2.927] for TT genotype, respectively), although the significance for TT genotype was lost after the correction for multiple testing. On the other hand, G allele and GG genotype had higher frequency in control group (55.3% vs. 42.4%; p = 0.002, OR = 0.596 [0.428–0.830] for G allele and 32.5% vs. 16.2%; p = 0.002, OR 0.4 [0.220–0.725] for GG genotype, respectively). In contrast to UC, no significant differences in allele or genotype frequencies of C1236T, G2677T/A and C3453T were observed in CD patients in comparison to the control group.

Furthermore, we compared the frequencies of allele carriers of C1236T, G2677T/A and C3453T in controls and UC group (Table 3). Carriers of A allele of G2677T/A SNP were excluded from the analysis since only one UC patient had that allele. As a result, we found that the carriers of T allele of all three SNPs were more frequent in UC patients than in healthy controls suggesting predisposing role of T variants of these SNPs in UC pathogenesis in our patients. Consistently, carriers of presumably protective C allele of C1236T were also found to be significantly more common in control group than in UC patients.

Finally, we determined distribution of three-locus (1236, 2677 and 3453) haplotypes and diplotypes in our study groups. A total of 10 haplotypes and 20 diplotypes were identified, but only three haplotypes (CGC, CGT and TTT) and six diplotypes (CGC/CGC, CGC/CGT, CGC/TTT, CGT/TTT, TTC/TTT and TTT/TTT) had frequencies higher than 5% and were included in the analysis (Table 4). CGC haplotype and CGC/CGC diplotype were found more common in healthy controls than in UC patients (46.9% vs. 34.3%; p = 0.003, OR = 0.593 [0.422–0.834] for CGC haplotype and 22.7% vs. 11.1%; p = 0.013, OR = 0.425 [0.213–0.848] for CGC/CGC diplotype, respectively) further validating potential protective role of 1236C, 2677G and 3453C alleles in UC. Similarly, TTT haplotype was significantly more frequent among UC patients (54% vs. 40.8%; p = 0.001, OR = 1.707 [1.226–2.376]), which was in concordance with allele/genotype/carry analyses recognizing T alleles of all three MDR1 SNPs as risk factors in UC. Consistent with this finding, we observed higher frequency of TTT/TTT diplotype in UC group compared to controls (26.3% vs. 18.8%), but the difference did not reach statistical significance (p = 0.122). On the other hand, TTT in conjunction with rare TTC haplotype (TTC/TTT) was associated with UC (p = 0.028, OR 4.468 [1.047–19.364]), but

| Table 3. Comparison between allele carriers of MDR1 SNPs in controls and UC group MDR1 SNP. |
|---------------------------------------------|
|                                      |
| Controls (n = 255) | UC (n = 99) |
|---------------------------------------------|
|                                      |
| C1236T (rs1128503) |                                      |
| C carrier 200 | 65 | 0.013** | 0.526 (0.315–0.876) |
| T carrier 170 | 83 | 0.001** | 2.594 (1.430–4.703) |
| G2677T/A (rs2032582) |                                      |
| G carrier 199 | 68 | 0.067 | 0.617 (0.368–1.036) |
| T carrier 168 | 82 | 0.002** | 2.498 (1.394–4.475) |
| C3435T (rs1045642) |                                      |
| C carrier 192 | 66 | 0.101 | 0.656 (0.396–1.088) |
| T carrier 185 | 86 | 0.004** | 2.503 (1.314–4.770) |

*p values were calculated using Chi-square test
**significant after adjustment for multiple test comparison
CI–confidence interval

https://doi.org/10.1371/journal.pone.0194536.t003
this nominal association did not withstand correction for multiple testing. Again, no significant difference in haplotype/diplotype distribution was recorded in CD in comparison to the control group.

**Discussion**

The present study is the first genetic association study that investigated allele and genotype patterns of three common polymorphisms in the *MDR1* gene (C1236T, G2677A/T and G3453T) in IBD patients from Serbia. Its results demonstrated a highly significant association of all three investigated SNPs with an overall susceptibility for UC. Moreover, we also observed significant difference in the haplotype and diplotype distributions between UC patients and healthy controls. In contrast, none of the analyzed SNPs was associated with CD patients in our cohort.

There is a great degree of controversy on the contribution of SNPs in the *MDR1* gene to IBD susceptibility. Regarding the C3435T and G2677T/A variants, the first published studies revealed significant association with UC and IBD in Whites from Germany and USA, respectively [15, 16], but subsequent studies only partially replicated the initial findings since they have produced contradictory results (Table 5). As for C3435T polymorphism, some studies found association of T allele and/or TT genotype with UC and not with CD, in German, Scottish, Japanese, Iranian and Croatian populations [15, 34–38], whereas many studies failed to demonstrate these associations in different populations [16, 17, 20–25, 39–51]. Rare data pointed even to the association of C3435T polymorphism with CD [52, 53]. Despite such discrepancy in results from different studies, it seems that mutant T allele of C3435T could be regarded as a risk factor for UC, since several meta-analyses confirmed the association of this variant with susceptibility to develop UC, but not CD [7, 17, 18, 20]. In our study, T allele of C3435T was clearly associated with UC which is in line with its presumed pathogenic role in the pathogenesis of this form of IBD. Similarly to C3435T, the association between triallelic G2677T/A SNP and IBD was extensively investigated with inconsistent results (Table 5). In our study, T allele was associated with UC patients, while wild G allele and GG genotype

| Table 4. Haplotype and diplotype frequencies of *MDR1* SNPs in controls, CD and UC groups. |
|---------------------------------------------|---------------------------------------------|-------------------------------|------------------|------------------|------------------|------------------|
| Haplotype | Controls (n = 255) | CD (n = 107) | UC (n = 99) | p value* | Controls (n = 255) | CD (n = 107) | UC (n = 99) | p value* |
| C G C | 239 (46.9) | 107 (50.0) | 68 (34.3) | 0.441 | 0.003** |
| C G T | 30 (5.9) | 14 (6.5) | 12 (6.1) | 0.735 | 0.928 |
| T T T | 208 (40.8) | 78 (36.4) | 107 (54.0) | 0.276 | 0.001** |
| Other | 33 (6.5) | 15 (7.0) | 11 (5.6) | 0.938 | 0.596 |
| Diplotype | Controls (n = 255) | CD (n = 107) | UC (n = 99) | p value* | Controls (n = 255) | CD (n = 107) | UC (n = 99) | p value* |
| C G C / C G C | 58 (22.7) | 26 (24.3) | 11 (11.1) | 0.752 | 0.013** |
| C G C / C G T | 15 (5.9) | 8 (7.5) | 2 (2.0) | 0.570 | 0.127 |
| C G C / T T T | 89 (34.9) | 39 (36.4) | 42 (42.4) | 0.777 | 0.188 |
| C G T / T T T | 11 (4.3) | 6 (5.6) | 5 (5.1) | 0.596 | 0.512 |
| T T C / T T T | 3 (1.2) | 2 (1.9) | 5 (5.1) | 0.606 | 0.028 |
| T T T / T T T | 48 (18.8) | 14 (13.1) | 26 (26.3) | 0.186 | 0.122 |
| Other | 31 (12.2) | 12 (11.2) | 8 (8.1) | 0.917 | 0.589 |

*p values were calculated using Chi-square test

**significant after adjustment for multiple test comparison

https://doi.org/10.1371/journal.pone.0194536.t004
Table 5. Summary of MDR1 association studies and meta-analyses in IBD.

| Study                        | Ref    | Population     | Number of cases/studies | Analyzed SNPs                  | Main results                                                                 |
|------------------------------|--------|----------------|--------------------------|-------------------------------|-------------------------------------------------------------------------------|
| **Association studies**      |        |                |                          |                               |                                                                               |
| Schwab et al. 2003           | 15     | German CD 126  | UC 149                   | C3435T                        | 3435T allele associated with UC                                              |
| Brant et al. 2003            | 16     | American CD 409| UC 119                   | C3435T, G2677T/A              | G2677 allele associated with IBD                                             |
| Croucher et al. 2003         | 39     | German and British CD 562 | UC 307                   | C3435T                        | No association                                                               |
| Glas et al. 2004             | 34     | German CD 135  | UC 123                   | C3435T                        | Association of 3435T allele with UC depending on the control group used     |
| Potocnik et al. 2004         | 40     | Slovenian CD 163| UC 144                   | C3435T, G2677T/A C1236T       | 2677T allele associated with UC TTT haplotype associated with UC             |
| Gazouli et al. 2004          | 41     | Greek CD 120   | UC 85                    | C3435T                        | No association                                                               |
| Palmieri et al. 2005         | 42     | Italian CD 478 | UC 468                   | C3435T, G2677T/A              | No association                                                               |
| Ho et al. 2005               | 35     | Scottish CD 268 | UC 335                   | C3435T, G2677T/A              | T allele and TT genotype of C3435T and G2677/3435T haplotype associated with UC |
| Ho et al. 2006               | 21     | Scottish CD 179 | UC 249                   | C3435T, C1236T                | No association                                                               |
| Osuga et al. 2006            | 36     | Japanese CD    | UC 66                    | C3435T, G2677T/A C1236T       | 3435T allele associated with later onset UC                                  |
| Onnie et al. 2006            | 17     | British CD 828 | UC 580                   | C3435T, G2677T/A              | 2677T associated with UC                                                    |
| Urcelay et al. 2006          | 53     | Spanish CD 321 | UC 330                   | C3435T, G2677T/A              | C allele and CC genotype of C3435T and 2677T/C3435 haplotype associated with CD |
| Oostenbrug et al. 2006       | 43     | Dutch CD 553   | UC 224                   | C3435T, C1236T                | No association                                                               |
| Lal et al. 2006              | 52     | Canadian CD 247| UC 112                   | C3435T                        | 3435T allele associated with CD                                              |
| Lee et al. 2006              | 44     | Korean CD 24   | UC 94                    | C3435T                        | No association                                                               |
| Fiedler et al. 2007          | 45     | German CD 244  | UC 144                   | C3435T, G2677T/A              | No association                                                               |
| Fischer et al. 2007          | 46     | Hungarian CD 265| UC 149                   | C3435T, G2677T/A              | No association                                                               |
| Farnood et al. 2007          | 37     | Iranian CD    | UC 300                   | C3435T                        | T allele, TT and CT genotypes of C3435T associated with UC                  |
| Ardizzone et al. 2007        | 47     | Italian CD 211 | UC 97                    | C3435T, G2677T/A              | No association                                                               |
| Sapmaz et al. 2008           | 48     | Turkish CD 35  | UC 82                    | G2677T/A                      | No association                                                               |
| Huebner et al. 2009          | 22     | New Zealand CD | UC 401                   | C3435T, G2677T/A C1236T       | G2677T and C1236T heterozygous protective for UC                            |
| Krupoves et al. 2009         | 54     | Canadian CD 270 | UC 401                   | C3435T, G2677T/A C1236T       | No association                                                               |
| Juyal et al. 2009            | 23     | Indian CD    | UC 270                   | C3435T, G2677T/A C1236T       | 1236T allele and TTT, TGT and 1236T/2677T haplotypes associated with UC     |
| Ostergaard et al. 2009       | 49     | Danish CD 373  | UC 541                   | C3435T, G2677T/A              | No association                                                               |
| Dudarewicz et al. 2012       | 50     | Polish CD 47   | UC 61                    | C3435T                        | No association                                                               |
| Brinar et al. 2013           | 38     | Croatian CD 199| UC 109                   | C3435T, G2677T/A              | T allele of G2677T/A, TT genotype of C3435T and 2677T/3435T haplotype associated with UC Heterozygous C3435T protective for CD |

(Continued)
dominated within control group, implying predisposing and protective roles of T and G variants, respectively. Our carrier analysis further supported possible pathogenic role of T allele in UC. Similar associations of T allele with UC were observed in British, Indian, Croatian and Slovenian studies [17, 23, 38, 40]. In contrast, G allele was associated with IBD as a risk factor in American patients [16] and as a protective factor for CD in Chinese study [25]. A number of studies failed to demonstrate any association of G2677T/A and UC or CD patients [35, 36, 42, 45–49, 53], indicating that this polymorphism of MDR1 may not confer susceptibility to IBD, as suggested by the negative results of two meta-analyses performed thus far [7, 18]. In contrast to C3435T and G2677T/A, C1236T polymorphism has been less extensively analyzed with regard to IBD (Table 5). The strongest association observed in our study was the association between T allele of C1236T and UC. The frequency TT genotype was also significantly higher in UC patients, while C allele and CC genotype were more common in healthy controls, suggesting predisposing and protective role of T and C allele, respectively. Again, our carrier analysis further substantiated these findings. Allele T or TT genotype of C1236T SNP have been already linked to UC susceptibility in Moroccan and North Indian IBD patients [20, 23], while C allele and CC genotype were associated with UC patients in China [24]. On the other hand, several studies found no association between C1236T and UC or CD [21, 25, 36, 40, 43] and two recent meta-analyses also failed to demonstrate such associations [18, 20].

In complex diseases, like IBD, haplotype analysis is potentially more informative than analysis of single polymorphisms, as it takes into account the combined effects of all SNPs tested and any variation within a region that might be in the linkage disequilibrium (LD) with them. Therefore, we determined whether three-locus (1236, 2677, 3435) haplotypes provide a stronger association with disease than individual SNPs in our cohort. As a result, both susceptible (TTT) and protective (CGC) haplotypes for UC were identified that can alter the risk for developing disease in a bidirectional fashion. The putative susceptible haplotype, which was strongly associated with our UC patients, contained mutant allelic variants (T variants) of all three SNPs that are believed to increase the risk to develop UC. On the other hand, the supposed protective haplotype that prevailed among healthy subjects in our cohort included wildtype alleles (C1236, G2677 and C3435) which were in previous studies occasionally shown to lower the risk for the disease. In line with this, CGC/CGC diplotype was also associated with UC.

| Study               | Ref. | Population        | Number of cases/studies | Analyzed SNPs                  | Main results                                                                 |
|---------------------|------|-------------------|-------------------------|--------------------------------|-------------------------------------------------------------------------------|
| Bonyadi et al. 2014 | 51   | Iranian Azeri Turks | CD 19, UC 97            | C3435T                         | No association                                                               |
| Cao et al. 2015     | 24   | Chinese           | CD / UC 61              | C3435T, C1236T                 | C allele and CC genotype of C1236T associated with UC                        |
| Senhaji et al. 2015 | 20   | Moroccan          | CD 77, UC 33            | C3435T, C1236T                 | TT genotype of C1236T associated with UC                                      |
| Yang et al. 2015    | 25   | Chinese           | CD 117, UC 39           | C3435T, G2677T/A, C1236T       | G2677 protective for CD                                                       |

| Meta-analyses       |      |                   |                         |                                |                                                                               |
|---------------------|------|-------------------|-------------------------|--------------------------------|-------------------------------------------------------------------------------|
| Annese et al. 2006  | 7    | Various           | 7 studies               | C3435T, G2677T/A              | T allele and TT genotype of C3435T associated with UC                        |
| Onnie et al. 2006   | 17   | Various           | 7 studies               | C3435T                         | 3435T associated with UC                                                     |
| Zintzaras et al. 2012 | 18  | Various           | 18 studies              | C3435T, G2677T/A, C1236T       | 3435T associated with UC, No association for G2677T/A and C1236T            |
| Wang et al. 2014    | 19   | Various           | 13 studies              | C3435T                         | No association                                                               |
| Senhaji et al. 2015 | 20   | Various           | 18 studies              | C3435T, C1236T                 | 3435T associated with IBD, No association for C1236T                         |
patients in our study. There are a limited number of studies that assessed the influence of three-locus (1236, 2677, 3435) haplotypes on IBD susceptibility and they found association between TTT and UC [23, 40]. Likewise, some two-locus haplotypes (namely, 1236T/2677T, G2677/3435T and 2677T/3435T) were also associated with UC [23, 35, 38, 45]. Finally, some studies did not find any association between haplotypes and susceptibility to develop UC [22, 25, 54]. Thus, our haplotype data are in accordance with our results from analyses of single polymorphisms as well as with results from most other studies, further validating important role of certain variants of C1236T, G2677T/A and C3435T SNPs in determining susceptibility to UC, but not CD.

Apparently, there is uncertainty concerning the role of C1236T, G2677T/A and C3435T polymorphisms in IBD pathogenesis due to conflicting results of the studies in different populations. The reasons for reported differences may be relatively small sample size in most studies leading to a lack of association due to low power, differences in study design and selection of control population. The importance of controls has already been shown in German study in which the association depended on the control group chosen by the investigators [34]. The discrepancy can also be explained by ethnic diversity. There is some evidence that the polymorphisms allele frequencies may be different in subpopulations and that the frequency of minor mutant alleles of MDR1 SNPs varies considerably between different populations (e.g. about 3% for C3435T compared to online hapmap database in Caucasians) [7, 38, 55]. Since the differences in MDR1 SNPs observed between patients and healthy subjects are quite modest, it is possible that the minor allele frequencies in the control groups account for the majority of different results in various studies [38]. In our study, the frequencies of alleles in control group were comparable to other European studies, especially those from the region where populations are believed to share the same origin [38, 40, 55]. Our findings of significant associations of C1236T, G2677T/A and C3435T SNPs with UC are in line with possible predisposing role of T variants of these polymorphisms in disease pathogenesis. However, it is not clear how those variants may confer susceptibility towards UC and why no such predisposition was observed in CD. Likely explanation would be that altered P-gp expression and/or function caused by MDR1 SNPs may result in an aberrant transport of potentially toxic xenobiotics and/or microbial products in individuals who harbor particular variant(s) making them more susceptible to develop UC, but not CD. The G2677T is a coding polymorphism resulting in substitution of alanine by serine and 2677T allele was shown to increase P-gp function [56], although other studies found no influence of this SNP on expression level, intracellular location or function of P-gp [57–59]. On the other hand, C1236T and C3435T are silent polymorphisms that do not cause change in amino acid sequence of P-gp. Nevertheless, C3435T SNP was associated with altered P-gp expression and function in some studies [12, 60], but other studies failed to confirm that [59, 61]. As for C1236T, no report has investigated so far whether this polymorphism may be functional. Despite limited and contradictory results, it is possible that all three polymorphisms (or at least some of them) may impact MDR1 gene expression and P-gp function, either alone or synergistically, as suggested by the association of TGT and TTT haplotypes with the function of P-gp [56, 62]. However, it cannot be excluded that some other unidentified causal variant (or variants) that is in LD with the analyzed MDR1 SNPs, affects expression and/or function of P-gp and thus confers susceptibility to develop UC.

The main question that is remaining is why highly powered GWAS have not found evidence for MDR1 polymorphism associations seen in candidate gene studies [63]. There are several possible explanations for the observed discrepancy. First, it is simply possible that MDR1 polymorphism associations have not been evaluated properly, as it might be the case for the triallelic variant (G2677T/A polymorphism). Second, GWAS are designed to screen the genome, based on the LD between genotyped SNPs and the potentially causative variants, so it
is possible that MDR1 polymorphisms have been missed because they have not been tagged by the genotyped SNPs or they may be located considerably far away from SNPs showing the disease association with UC. Next, because of the stringent significance thresholds due to multiple testing corrections, GWAS have less power than more confined studies, such as candidate gene studies, to detect genes with small effects on disease development, which may lead to a lack of associations of MDR1 with UC in GWAS. Further, it is believed that mutations in MDR1 could affect the uptake of bacterial toxins and xenobiotics, which may add an element of exposure to a complexity of UC pathogenesis, similarly to infectious diseases. Thus, certain variants might only be detectable in patients exposed to some (un)known environmental factors. Likewise, other factors, including IBD subphenotypes and interethnic differences of the populations studied may also affect results from various GWAS, as previously mentioned. A recent GWAS performed in African Americans with IBD has identified loci associated with UC only in this population, in addition to loci identified previously in European populations, further emphasizing the importance of the population included in the study [64]. On the other hand, it is possible that high-powered studies did not show evidence simply because there is no association of MDR1 polymorphisms with UC. Or it may be that the negative candidate gene studies have not been published enough or corrections for multiple testing in published studies have not been done leading to false positive results. It is also possible that the candidate gene studies, which do not genetically match controls rigorously as GWAS, may be tending to report only stratification in allele frequencies between cases and controls. It is anticipated that the use of integrated analysis of genome (whole genome sequencing) and expression data (whole exome sequencing) will overcome some of the limitations of both types of genetic studies, which might confirm associations of some variants of MDR1 with UC in the near future. Finally, it is important to underscore some limitations of this study. Our study group was relatively small. Nevertheless, the power of our study was fairly adequate as it ranged from 49.6% for C3435T, and 64.6% for G2677T/A, up to 71.9% for C1236T. Also, all IBD patients were from the tertiary referral center, and thus most of them had severe forms of disease. Consequently, patients with limited disease with low activity are underrepresented in our study. Thus, like in all association studies on complex diseases, replication of the associations in larger studies in ethnically similar populations is required to validate our findings.

Conclusions

This is the first report on the prevalence of the MDR1 polymorphisms in patients with IBD from Serbia, and one of the few performed so far in Eastern European countries. It is also one of the rare studies that included correction for multiple testing and still found associations of all three common MDR1 polymorphisms (C1236T, G2677T/A and C3435T) with UC, with some of associations being among the strongest reported thus far with relatively high ORs, as for T allele of C1236T SNP. Moreover, susceptible and protective haplotypes for UC were also identified in our population. Therefore, our study may provide more insight into the complexities of the contribution of MDR1 gene in determining susceptibility towards UC and add some valuable data in the search for reliable biomarkers in IBD.

Author Contributions

Conceptualization: Milos Markovic.

Data curation: Dragana Mijac, Vera Mijac, Milos Markovic.

Formal analysis: Dragana Mijac, Vera Mijac, Vladimir Perovic, Natasa Milic, Milos Markovic.

Funding acquisition: Vera Pravica.
Investigation: Dragana Mijac, Irena Vukovic-Petrovic, Srdjan Djuranovic, Daniela Bojic, Dragana Popovic, Djordje Culafic, Miodrag Krstic, Goran Jankovic.

Methodology: Dragana Mijac, Irena Vukovic-Petrovic, Milos Markovic.

Project administration: Vera Pravica, Milos Markovic.

Resources: Dragana Mijac, Irena Vukovic-Petrovic, Vladimir Perovic.

Supervision: Natasa Milic, Vera Pravica, Milos Markovic.

Validation: Dragana Mijac, Natasa Milic, Milos Markovic.

Visualization: Dragana Mijac, Irena Vukovic-Petrovic, Milos Markovic.

Writing – original draft: Dragana Mijac, Vera Mijac, Milos Markovic.

Writing – review & editing: Dragana Mijac, Milos Markovic.

References

1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12: 205–217. https://doi.org/10.1038/nrgastro.2015.34 PMID: 25732745

2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066–2078. https://doi.org/10.1056/NEJma0804647 PMID: 19923578

3. Gordon H, Trier Moller F, Andersen V, Harbord M. Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies. Inflamm Bowel Dis. 2015; 21: 1428–1434. https://doi.org/10.1097/MIB.0000000000000393 PMID: 25895112

4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307–317. https://doi.org/10.1038/nature10209 PMID: 21677747

5. Thiebaut F, Tsuruo T, Harada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987; 84: 7735–7738. PMID: 2444983

6. Fricker G, Drewe J, Huwyler J, Guttmann H, Béglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996; 116: 1841–1847. PMID: 8842452

7. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andreu A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol. 2006; 12: 3636–3644. https://doi.org/10.3748/wjg.v12.i23.3636 PMID: 16773678

8. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003; 52: 759–766. PMID: 12692067

9. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998; 161: 5733–5744. PMID: 9820555

10. Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998; 95: 7502–7507. PMID: 9636179

11. Langmann T, Moehle C, Mauere R, Scharl M, Liebisch G, Zahn A, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004; 127: 26–40. PMID: 15236169

12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein activity in vivo. Proc Natl Acad Sci USA. 2000; 97: 3473–3478. https://doi.org/10.1073/pnas.050585397 PMID: 10716719

13. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Bio Pharm Bull. 2004; 27: 939–948. PMID: 15236719

14. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma ML, et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics. 2007; 8: 29–39. https://doi.org/10.2217/14622416.8.1.29 PMID: 17167507
15. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003; 124: 26–33. DOI: 10.1053/gast.2003.50010 PMID: 1212026

16. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73: 1282–1292. DOI: 10.1086/379927 PMID: 14610718

17. Onnie CM, Fisher SA, Pattni R, Sanders J, Forbes A, Lewis CM, et al. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006; 12: 263–271. DOI: 10.1097/01.MIB.0000209791.98866.ba PMID: 16633048

18. Zintzaras E. Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease? Inflamm Bowel Dis. 2012; 18: 562–572. DOI: 10.1002/ibd.21728 PMID: 21887726

19. Wang J, Guo X, Yu S, Zhang J, Song J, Ji M, et al. MDR1 C3435T polymorphism and inflammatory bowel disease risk: a meta-analysis. Mol Biol Rep. 2014; 41: 2679–2685. DOI: 10.1007/s11033-014-3127-4 PMID: 24449364

20. Senhaji N, Kassogue Y, Fahimi M, Serbati N, Badre W, Nadifi S. Genetic Polymorphisms of Multidrug Resistance Gene-1 (MDR1/ABCB1) and Glutathione S-Transferase Gene and the Risk of Inflammatory Bowel Disease among Moroccan Patients. Mediators Inflamm. 2015; 2015: 248060. DOI: 10.1155/2015/248060 PMID: 26604430

21. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet. 2006; 15: 797–805. DOI: 10.1093/hmg/ddi494 PMID: 16434479

22. Huebner C, Browning BL, Petermann I, Han DY, Philpott M, Barclay M, et al. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1784–1793. DOI: 10.1002/ibd.20198 PMID: 19885447

23. Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet Genomics. 2009; 19: 77–85. DOI: 10.1097/PPG.0b013e32831a9abe PMID: 19005421

24. Cao Y, Qu C, Chen Y, Li L, Wang X. Association of ABCB1 polymorphisms and ulcerative colitis susceptibility. Int J Clin Exp Pathol. 2015; 8: 943–947. PMID: 25755800

25. Yang Q, Chen BL, Zhang QS, Zhu ZH, Hu B, He Y, et al. Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population. J Dig Dis. 2015; 16: 22–30. DOI: 10.1016/j.jdd.2015.05.004 PMID: 25346426

26. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013; 6: 33–47. DOI: 10.4137/CGast.S12731 PMID: 24833941

27. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet. 2004; 13: 783–797. DOI: 10.1093/hmg/ddh099 PMID: 14976162

28. Van Assche G, Dignass A, Panes J, Beaugerie L, Maaser C, Chowers Y, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4: 7–27. DOI: 10.1016/j.crohns.2009.12.003 PMID: 21122488

29. Dignass A, Eliaikim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6: 965–990. DOI: 10.1016/j.crohns.2012.09.003 PMID: 23040452

30. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated consensus on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006; 12: 263–271. DOI: 10.1097/01.MIB.0000209791.98866.ba PMID: 16633048

31. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated consensus on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006; 12: 263–271. DOI: 10.1097/01.MIB.0000209791.98866.ba PMID: 16633048

32. Excoffier L, Lischer HEL. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2010; 10: 564–567. DOI: 10.1111/j.1755-0998.2010.02847.x PMID: 21565059
34. Glas J, Török HP, Schiemann U, Folvaczny C. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology. 2004; 126: 367.
35. Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in patients with Crohn's disease. Gastroenterology. 2005; 128: 288–296. PMID: 15685540
36. Osuga T, Sakaeda T, Nakamura T, Yamada T, Koyama T, Tamura T, et al. MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese. Biol Pharm Bull. 2006; 29: 324–329. PMID: 16462040
37. Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R, et al. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Colorectal Dis. 2007; 22: 999–1003. https://doi.org/10.1007/s00384-007-0270-6 PMID: 17242936
38. Brinar M, Cukovic-Cavka S, Bozina N, Ravic KG, Markos P, Ladic A, et al. MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterology. 2013; 13: 57. https://doi.org/10.1186/1471-230X-13-57 PMID: 23537364
39. Croucher PJ, Mascheretti R, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology. 2003; 125: 1919–1920. PMID: 14727637
40. Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005; 22: 1129–1138. https://doi.org/10.1111/j.1365-2036.2005.02701.x PMID: 16305727
41. Gazouli M, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonomopoulos J. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology. 2004; 126: 367–369.
42. Palmieri O, Latiano A, Valvano R, D’Incà R, Vecchi M, Sturiniolo GC, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005; 22: 1129–1138. https://doi.org/10.1111/j.1365-2036.2005.02701.x PMID: 16305727
43. Oostenbrug LE, Dijkstra G, Nolte IM, van Dulleman HM, Oosterom E, Faber KN, et al. Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol. 2006; 41: 1174–1182. https://doi.org/10.1080/00365520600575746 PMID: 16990202
44. Lee BI, Choi KY, Lee KM, Chung WC, Kim BW, Choi H, et al. Is C3435T MDR1 polymorphism linked to inflammatory bowel disease or colorectal cancer in Korean? Korean J Gastroenterol. 2006; 47: 22–29. PMID: 16434865
45. Fiedler T, Bünig C, Reuter W, Pitre G, Gentz E, Schmidt HH, et al. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease. Eur J Clin Pharmacol. 2007; 63: 917–925. https://doi.org/10.1007/s00228-007-0334-0 PMID: 17665184
46. Fischer S, Lakatos PL; Hungarian IBD Study Group, Lakatos L, Kovacs A, Molnar T, et al. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases. Scand J Gastroenterol. 2007; 42: 726–733. https://doi.org/10.1080/00365520601101559 PMID: 17505995
47. Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 516–523. https://doi.org/10.1002/ibd.20108 PMID: 17260393
48. Sarpmaz A, Ozen Karataylı SC, Dağlı U, Kılıç ZM, Türünç M, Celiş Y, et al. Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease. Turk J Gastroenterol. 2008; 19: 168–173. PMID: 19115152
49. Östergaard M, Ernst A, Labouriau R, Dagilewicz E, Krarup HB, Christensen M, et al. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol. 2009; 44: 65–73. https://doi.org/10.1080/00365520802040826 PMID: 18819034
50. Dudarewicz M, Barańska M, Rychlik-Sych M, Trzcinski R, Dziki A, Skrętkowicz J. C3435T polymorphism of the ABCB1/MDR1 gene encoding P-glycoprotein in patients with inflammatory bowel disease in a Polish population. Pharmacol Rep. 2012; 64: 343–350. PMID: 22661185
51. Bonyadi MJ, Gerami SM, Soveri MH, Khoshbaten M. Effect of the C3435T polymorphism of the multidrug resistance 1 gene on the severity of inflammatory bowel disease in Iranian Azeri Turks. Saudi J Gastroenterol. 2013; 19: 172–176. https://doi.org/10.4103/1319-3767.114515 PMID: 23828747
52. Lal S, Stempak JM, Law C, Eldadah AA, Silverberg MS. Association between the C3435T polymorphism of the MDR1 gene and Crohn’s disease. Inflamm Bowel Dis. 2006; 12: 1006–1007. https://doi.org/10.1097/01.mib.0000228999.37090.e1 PMID: 17012973
53. Urcelay E, Mendoza JL, Martín MC, Mas A, Martínez A, Taxonera C, et al. MDR1 gene: susceptibility in Spanish Crohn’s disease and ulcerative colitis patients. Inflamm Bowel Dis. 2006; 12: 33–37. PMID: 16374256

54. Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, Lambrette P, et al. Associations between ABCB1/MDR1 gene polymorphisms and Crohn’s disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis. 2009; 15: 900–908. https://doi.org/10.1002/ibd.20849 PMID: 19107781

55. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plasman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep. 2011; 63: 808–814. PMID: 21857092

56. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70: 189–199. https://doi.org/10.1067/mcp.2001.117412 PMID: 11503014

57. Tanabe M, Ieiri I, Naga N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297: 1137–1143. PMID: 11366939

58. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002; 62: 1–6. PMID: 12065748

59. Siegmun W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002; 72: 572–583. https://doi.org/10.1067/mcp.2002.127739 PMID: 12426521

60. Hitzl M, Drescher S, van der Kuip H, Schäffler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001; 11: 293–298. PMID: 11434506

61. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pähkla R, Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest. 2003; 33: 261–267. PMID: 12641546

62. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. 2006; 95: 2293–2308. https://doi.org/10.1002/jps.20717 PMID: 16883550

63. Cario E. P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers. World J Gastroenterol. 2017; 23: 1513–1520. https://doi.org/10.3748/wjg.v23.i9.1513 PMID: 28321153

64. Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, et al. Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology. 2017; 152: 206–217. https://doi.org/10.1053/j.gastro.2016.09.032 PMID: 27693347